Published on
June 22, 2016
- 00:08 GMT
OGD2 Pharma and Green Cross LabCell start collaboration for developing NK-cell therapeutics targeting the O-acetyl-GD2 cancer ...
Nantes, France and Seoul, Korea, June 21, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with …
Distribution channels:
Technology
